Heres what we work with: GLP-1 weight loss peptides Semaglutide and tirzepatide for appetite regulation, metabolic improvement, and sustainable fat loss
A large study of more than 2 million people with type 2 diabetes across 70 healthcare organizations suggests that adults prescribed a GLP-1RA had a 12% higher risk for developing a new cough persisting for more than 8 weeks, compared with people prescribed other medications, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) Read More Trends show that some patients are choosing to microdose their glucagon-like peptide 1 receptor agonists (GLP-1RA) prescriptions for diabetes and weight loss, whether a provider advises it or not
An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice
Managing weight or diabetes is often overwhelming, especially when faced with the ever-expanding array of medication options
This means that Tirzepatide may be more effective in weight loss
Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand.Thibault, what are the first countries seeing the introduction of sema generics
